Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective study assessing the effect of conversion from twice-daily tacrolimus to once-daily tacrolimus-advagraf on dosage change and intra-patient variability (IPV) in tacrolimus exposure

X
Trial Profile

A retrospective study assessing the effect of conversion from twice-daily tacrolimus to once-daily tacrolimus-advagraf on dosage change and intra-patient variability (IPV) in tacrolimus exposure

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tacrolimus (Primary)
  • Indications Renal transplant rejection
  • Focus Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 29 Aug 2019 Results determining change in IPV and total daily dosage of tacrolimus after converting from Tacrolimus bid to Advagraf published in the Transplantation Proceedings
    • 17 Nov 2017 New trial record
    • 27 Sep 2017 Results presented at the 18th Congress of the European Society for Organ Transplantation

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top